Skip to main content
Premium Trial:

Request an Annual Quote

Igenica Raises $24M in Series B Round

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) — Igenica today said it has completed a Series B financing round, raising $24 million.

The round was led by The Column Group, OrbiMed Advisors, and 5AM Ventures. The funds will be used to expand and accelerate Igenica's drug discovery and development efforts using its proteomics- and antibody-based platforms, Igenica said in a statement.

The proteomics platform, called sTAg, identifies new surface antigens that are amenable to antibody targeting in cancer. The monoclonal antibody platform, called iTAb, is a function-based de novo method for generating and screening antibody drug candidates against tumor antigens.

Based in Burlingame, Calif., Igenica previously had raised about $5 million.

The Scan

Genome Sequences Reveal Range Mutations in Induced Pluripotent Stem Cells

Researchers in Nature Genetics detect somatic mutation variation across iPSCs generated from blood or skin fibroblast cell sources, along with selection for BCOR gene mutations.

Researchers Reprogram Plant Roots With Synthetic Genetic Circuit Strategy

Root gene expression was altered with the help of genetic circuits built around a series of synthetic transcriptional regulators in the Nicotiana benthamiana plant in a Science paper.

Infectious Disease Tracking Study Compares Genome Sequencing Approaches

Researchers in BMC Genomics see advantages for capture-based Illumina sequencing and amplicon-based sequencing on the Nanopore instrument, depending on the situation or samples available.

LINE-1 Linked to Premature Aging Conditions

Researchers report in Science Translational Medicine that the accumulation of LINE-1 RNA contributes to premature aging conditions and that symptoms can be improved by targeting them.